Retreatment of Recurrent Head and Neck Cancer in a Previously Irradiated Field

Seminars in Radiation Oncology

Volumn 22, Issue 3, 2012, Pages 214-219

  Wong, Stuart J ^a   Bourhis, Jean ^b   Langer, Corey J ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CELECOXIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; HYDROXYUREA; PACLITAXEL;

BLEEDING; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG DOSE ESCALATION; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; THROMBOSIS;

CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; NEOPLASMS, SQUAMOUS CELL; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY DOSAGE; RETREATMENT;

EID: 84862137892     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.03.006     Document Type: Review

References (37)

1. Taussky D., Dulguerov P., Allal A.S. Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas. Head Neck 2005, 27:182-186.
2. Spencer S.A., Harris J., Wheeler R.H., et al. RTOG 96-10: Reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001, 51:1299-1304.
3. Langer C.J., Harris J., Horwitz E.M., et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: Results of radiation therapy oncology group protocol 9911. J Clin Oncol 2007, 25:4800-4805.
4. Janot F. Randomized trial of postoperative re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. J Clin Oncol 2008, 26:5518-5523.
5. Spencer S.A., Harris J., Wheeler R.H., et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008, 30:281-288.
6. McDonald M.W., Moore M.G., Johnstone P.A. Risk of carotid blowout after reirradiation of the head and neck: A systematic review. Int J Radiat Oncol Biol Phys 2011, 82:1083-1089.
7. Choe K.S., Haraf D.J., Solanki A., et al. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer 2011 Jun 13, [Epub ahead of print].
8. Tanvetyanon T., Padhya T., McCaffrey J., et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol 2009, 27:1983-1991.
9. Machtay M., Rosenthal D.I., Chalian A.A., et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004, 59:72-77.
10. Villaflor V.M., Haraf D., Salama J.K., et al. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol 2011, 22:2501-2507.
11. Haraf D.J., Weichselbaum R.R., Vokes E.E. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: A potentially curable disease. Ann Oncol 1996, 7:913-918.
12. De Crevoisier R., Bourhis J., Domenge C., et al. Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998, 16:3556-3562.
13. Sulman E.P., Schwartz D.L., Le T.T., et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009, 73:399-409.
14. Lee N., Chan K., Bekelman J.E., et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 68:731-740.
15. Popovtzer A., Gluck I., Chepeha D.B., et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: Implications for defining the targets. Int J Radiat Oncol Biol Phys 2009, 74:1342-1347.
16. Zwicker F., Roeder F., Hauswald H., et al. Reirradiation with intensity-modulated radiotherapy in recurrent head and neck cancer. Head Neck 2011, 33:1695-1702.
17. Sher D.J., Haddad R.I., Norris C.M., et al. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer 2010, 116:4761-4768.
18. Goldstein D.P., Karnell L.H., Yao M., et al. Outcomes following reirradiation of patients with head and neck cancer. Head Neck 2008, 30:765-770.
19. Chen A.M., Farwell D.G., Luu Q., et al. Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011, 80:669-676.
20. Trotti A., Pajak T.F., Gwede C.K., et al. TAME: Development of a new method for summarising adverse events of cancer treatment by the radiation therapy Oncology Group. Lancet Oncol 2007, 8:613-624.
21. Roh K.W., Jang J.S., Kim M.S., et al. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009, 74:1348-1355.
22. Unger K.R., Lominska C.E., Deeken J.F., et al. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010, 77:1411-1419.
23. Cengiz M., Özyiǧit G., Yazici G., et al. Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011, 81:104-109.
24. Heron D.E., Rwigema J.C., Gibson M.K., et al. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: A single institution matched case-control study. Am J Clin Oncol 2011, 34:165-172.
25. Kao J., Genden E.M., Chen C.T., et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 2011, 117:3173-3181.
26. Rusthoven K.E., Feigenberg S.J., Raben D., et al. Initial results of a phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010, 78:1020-1025.
27. Zwicker F., Roeder F., Thieke C., et al. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol 2011, 187:32-38.
28. Balermpas P., Hambek M., Seitz O., et al. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol 2009, 185:775-781.
29. Seiwert T.Y., Haraf D.J., Cohen E.E., et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008, 26:1732-1741.
30. Cohen E.E., Rosine D., Haraf D.J., et al. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 67:678-684.
31. Van Waes C., Chang A.A., Lebowitz P.F., et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005, 63:1400-1412.
32. Milas L., Fang F.M., Mason K.A., et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 2007, 67:568-572.
33. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
34. Nasu S., Ang K.K., Fan Z., et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001, 51:474-477.
35. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000, 6:701-708.
36. Nakata E., Hunter N., Mason K., et al. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 2004, 59:1163-1173.
37. Wong S.J., Machtay M., Li Y. Locally recurrent, previously irradiated head and neck cancer: Concurrent re-irradiation and chemotherapy, or chemotherapy alone?. J Clin Oncol 2006, 24:2653-2658.